People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says

Nbcwashington · May 21, 2026 · 594 words · By Berkeley Lovelace Jr; NBC News

Obesity Treatment Pharmaceutical Competition Medical Innovation

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Obesity Treatment

Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight, about 85 pounds, in a late-stage clinical trial, the drugmaker said in a news release Thursday.

Claims checked 19

Techniques found 1

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center80%

Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

The results are on par with bariatric surgery, which helps people lose on average 25% to 35% of their total body weight within one to two years.

Common ground

Stream NBC4 newscasts for free right here, right now.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Obesity Treatment story?
What evidence would most clearly confirm or weaken the claim that A smaller group of patients with severe obesity continued to take the drug for up to 104 weeks and lost an average of 85 pounds?
How does this story connect Obesity Treatment with Pharmaceutical Competition over the next few days?

open_in_new Read the original article: https://www.nbcwashington.com/news/health/eli-lilly-weight-loss-drug-retatrutide…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 70% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 19 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 9

check_circle Corroborated 3

help Insufficient Evidence 2

info Single Source 2

verified Verified By Reference 1

verified Verified 1

cancel Disputed 1

schedule

Claim 1: “A smaller group of patients with severe obesity continued to take the drug for up to 104 weeks and lost an average of 85 pounds.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 2: “compared with placebo, patients taking retatrutide also had more reports of unusual or uncomfortable skin sensations and urinary tract infections.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 3: “Lilly’s Zepbound, a double agonist, mimics GLP-1 and GIP.”

CORROBORATED

Multiple sources confirm Zepbound is a dual agonist mimicking both GLP-1 and GIP.

travel_explore

web search NEUTRAL — Both medications mimic the GLP-1 hormone, but Zepbound also mimics a second hormone: GIP. This may be why Zepbound can result in more weight loss than Wegovy. The medications are also approved for sli…
https://www.weightwatchers.com/us/blog/weight-loss/zepbound-…

travel_explore

web search NEUTRAL — Zepbound vs. retatrutide: How do they work? Like Lilly’s other tirzepatide medication, Mounjaro®, Zepbound is a dual agonist that mimics GLP-1/GIP hormones and promotes weight loss by slowing digestio…
https://joinfound.com/blog/zepbound-vs-retatrutide-how-these…

travel_explore

web search NEUTRAL — Zepbound is a dual GIP and GLP-1 receptor agonist, which means it activates both incretin pathways to enhance blood sugar control and support effective, long-term weight loss.
https://www.joincalibrate.com/resources/glp-1-agonist-list

schedule

Claim 4: “Participants taking the highest weekly dose of retatrutide lost, on average, 28% of their body weight, about 70 pounds, with nearly half losing 30% or more.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 5: “Lilly’s results are based on a phase 3 trial of about 2,300 patients with obesity or who are overweight.”

INSUFFICIENT EVIDENCE

No evidence was provided in the search results regarding the specific number of patients (2,300) in the phase 3 trial.

verified

Claim 6: “Retatrutide, however, is a so-called triple agonist — in addition to GLP-1, it also mimics the hormones GIP and glucagon.”

VERIFIED BY REFERENCE

Wikipedia and medical research summaries explicitly define retatrutide as a triple agonist targeting GLP-1, GIP, and glucagon receptors.

travel_explore

web search NEUTRAL — It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company…
https://en.wikipedia.org/wiki/Retatrutide

travel_explore

web search NEUTRAL — Retatrutide is a novel triple agonist targeting the receptors of glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/

travel_explore

web search NEUTRAL — Retatrutide is an investigational triple-agonist injection (GLP-1, GIP & glucagon) that’s showing the strongest weight loss results yet in clinical trials.
https://www.joinvoy.com/weight-loss/medications/retatrutide

info

Claim 7: “bariatric surgery, which helps people lose on average 25% to 35% of their total body weight within one to two years”

SINGLE SOURCE

While the evidence confirms what bariatric surgery is and its purpose, none of the provided sources specify the average weight loss percentage (25% to 35%) or the timeframe (one to two years).

travel_explore

web search NEUTRAL — The term is also used in the medical field as somewhat of a euphemism to refer to people of larger sizes without regard to their participation in any treatment specific to weight loss, such as medical…
https://en.wikipedia.org/wiki/Bariatrics

travel_explore

web search NEUTRAL — Dec 17, 2025 · Bariatric surgery (weight loss surgery) is an obesity treatment. It works by making changes to your digestive system that limit how much food your stomach can hold.
https://my.clevelandclinic.org/health/treatments/bariatric-s…

travel_explore

web search NEUTRAL — 6 days ago · Gastric bypass and other types of weight-loss surgery — also called bariatric or metabolic surgery — involve making changes to your digestive system to help you lose weight.
https://www.mayoclinic.org/tests-procedures/bariatric-surger…

schedule

Claim 8: “The rate of people dropping out of the trial was higher than what was seen for Zepbound but similar to rates seen with Wegovy, Lilly said.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 9: “Lilly has not yet filed for Food and Drug Administration approval for retatrutide.”

CORROBORATED

Multiple sources explicitly state that retatrutide is not yet FDA approved and that Eli Lilly has not yet filed for approval.

travel_explore

web search NEUTRAL — Is Retatrutide FDA Approved in 2026? Current FDA Approval Status: Not Approved.No trial halts for safety have been reported, though adverse events are closely monitored[2][5]. These milestones pave th…
https://www.retatruti.de/en/articles/is-retatrutide-fda-appr…

travel_explore

web search NEUTRAL — It has not been reviewed or approved by any regulatory agency, and no one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial. Lilly continues to war…
https://www.lilly.com/news/stories/what-to-know-about-retatr…

travel_explore

web search NEUTRAL — Is retatrutide approved by the FDA? No. As of April 2026, retatrutide is investigational. Phase 3 trials in the TRIUMPH program are ongoing, and Eli Lilly has not yet filed for FDA approval.
https://www.getpeptidewise.com/compare/retatrutide-vs-tirzep…

schedule

Claim 10: “patients taking the highest dose of Zepbound lost around 21% of their body weight over 72 weeks”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 11: “Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight, about 85 pounds, in a late-stage clinical trial”

CORROBORATED

Multiple independent web search results (NBC New York and other news reports) confirm that retatrutide helped participants lose up to 30% of body weight, approximately 85 pounds, in a late-stage clinical trial.

travel_explore

web search NEUTRAL — The Eli Lilly weight-loss drug mimics three gut hormones.Retatrutide, ‘Triple G’ Anti-Obesity Drug, Leads to Weight Loss of Up to 85 Pounds. The experimental weight-loss drug is not yet FDA approved, …
https://www.today.com/health/diet-fitness/retatrutide-weight…

travel_explore

web search NEUTRAL — Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight in a late-stage clinical trial.
https://www.nbcnewyork.com/news/health/eli-lilly-weight-loss…

travel_explore

web search NEUTRAL — Participants in a late-state clinical trial of Eli Lilly's new weight-loss drug, retatrutide, lost up to 30% of their body weight — approximately 85 pounds – the pharmacuetical company announced on Th…
https://justthenews.com/politics-policy/health/ely-lillys-ne…

schedule

Claim 12: “patients taking the highest dose of Wegovy lost around 15% after 68 weeks”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 13: “Nausea, constipation and diarrhea were among the side effects of retatrutide”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 14: “The trial ran for 80 weeks.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 15: “The drug company did not publish the full results in a medical journal.”

INSUFFICIENT EVIDENCE

No evidence was provided regarding whether the full results were published in a medical journal or not.

verified

Claim 16: “Retatrutide is in the same class of medications as Wegovy and Zepbound, which mimic a hormone called GLP-1.”

VERIFIED

Evidence from lilly.com and other medical sources confirms that retatrutide, Wegovy, and Zepbound all mimic the GLP-1 hormone.

travel_explore

web search NEUTRAL — Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GI…
https://www.lilly.com/news/stories/what-to-know-about-retatr…

travel_explore

web search NEUTRAL — Apr 14, 2026 · Learn what Retatrutide is, how it works, expected weight-loss results, side effects, and when it may be approved for obesity treatment.
https://www.drugs.com/retatrutide.html

travel_explore

web search NEUTRAL — 14 hours ago · The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-r…

cancel

Claim 17: “severe obesity, classified as a body mass index of at least 35”

DISPUTED

The claim states severe obesity is a BMI of at least 35. However, evidence from medical sources indicates that 'Obesity class III' (severe/extreme obesity) is typically BMI ≥ 40, though some definitions include BMI ≥ 35 if serious comorbid conditions are present.

travel_explore

web search NEUTRAL — Numbers and Classifications of Body Mass Index. Severely underweight individuals: BMI <16.5 kg/m².Obesity class III: BMI ≥40 kg/m² (also referred to as severe, extreme, or massive obesity).
https://pubmed.ncbi.nlm.nih.gov/34662049/

travel_explore

web search NEUTRAL — Historically, a body mass index (BMI) ≥ 40 has been defined as “morbid” or “extreme” obesity.This report introduced the term “clinically severe” obesity. Clinically severe obesity is defined as: BMI ≥…
https://www.pinsonandtang.com/resources/morbid-and-severe-ob…

travel_explore

web search NEUTRAL — Body mass index (BMI) is a calculated measure of weight relative to height. For adults, BMI is categorized into underweight, healthy weight, overweight, and obesity.
https://www.cdc.gov/bmi/adult-calculator/index.html

info

Claim 18: “It has said it expects to file for approval as early as this year.”

SINGLE SOURCE

The provided evidence for this claim consists of search results for a 2019 horror film named 'Eli', which is completely irrelevant to Eli Lilly's drug filing timeline.

travel_explore

web search NEUTRAL — Eli: Directed by Ciarán Foy. With Charlie Shotwell, Kelly Reilly, Max Martini, Lili Taylor. A boy receiving treatment for his auto-immune disorder discovers that the house he's living in isn't as safe…
https://m.imdb.com/title/tt5294518/

travel_explore

web search NEUTRAL — Endless entertainment starting at $8.99 Endless entertainment starting at $8.99 Eli
https://www.netflix.com/title/80206910

travel_explore

web search NEUTRAL — Eli is a 2019 American supernatural horror film directed by Ciarán Foy from a screenplay by David Chirchirillo, Ian Goldberg, and Richard Naing, based on a story by Chirchirillo.
https://en.m.wikipedia.org/wiki/Eli_(2019_film)

schedule

Claim 19: “There’s about 10% of patients that don’t respond to GLP-1s”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.